Editas Medicine presents preclinical data on gene editing at ASGCT, aiming to develop candidates for hematopoietic and liver therapies by 2025. Editas Medicine, Inc. announced its progress in the ...
Verve Therapeutics said Sunday it has generated the first human proof-of-concept data for its in vivo base editing therapy VERVE-101—the first base editing treatment to reach the clinic—in patients ...
Gene editing is growing up. Ten years after Science magazine named CRISPR its 2015 “Breakthrough of the Year,” this revolutionary gene editing technology has become a workhorse of modern biology. In ...
Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved ...
Verve Therapeutics has published the first data on an in vivo base editing program in humans, giving the world an early look at the effects of a cholesterol-busting candidate that could become part of ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies ...
BOSTON--(BUSINESS WIRE)--hC Bioscience, a biopharmaceutical company developing a fundamentally novel approach to treating genetic diseases through tRNA-based protein editing, today presented ...
Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort ...
- New preclinical data for the PBGENE-DMD final clinical candidate demonstrates an increase in dystrophin positive muscle cells across key muscle types, potentially driven by editing of muscle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results